Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Issues Earnings Results, Misses Estimates By $0.08 EPS

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) released its quarterly earnings data on Tuesday. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08), Zacks reports. The company had revenue of $180.85 million for the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.Kiniksa Pharmaceuticals International’s revenue for the quarter was up 61.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.18) earnings per share.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ:KNSA opened at $37.47 on Tuesday. The firm’s fifty day moving average is $37.00 and its 200-day moving average is $31.33. Kiniksa Pharmaceuticals International has a 52 week low of $17.82 and a 52 week high of $42.05. The firm has a market cap of $2.78 billion, a P/E ratio of 83.27 and a beta of 0.16.

Wall Street Analyst Weigh In

KNSA has been the subject of several recent research reports. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, July 29th. The Goldman Sachs Group upped their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Citigroup upped their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Finally, TD Cowen initiated coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a “buy” rating and a $60.00 price target for the company. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $50.29.

Insider Activity

In other news, COO Eben Tessari sold 12,368 shares of the company’s stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $37.67, for a total value of $465,902.56. Following the sale, the chief operating officer directly owned 28,684 shares of the company’s stock, valued at approximately $1,080,526.28. This represents a 30.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ross Moat sold 3,523 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $35.31, for a total transaction of $124,397.13. Following the completion of the sale, the insider directly owned 9,415 shares in the company, valued at approximately $332,443.65. This represents a 27.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 730,895 shares of company stock valued at $26,574,480. Company insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Kiniksa Pharmaceuticals International by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after acquiring an additional 1,002 shares in the last quarter. Osaic Holdings Inc. bought a new position in Kiniksa Pharmaceuticals International during the second quarter worth $31,000. Cerity Partners LLC boosted its stake in Kiniksa Pharmaceuticals International by 2.9% during the second quarter. Cerity Partners LLC now owns 41,904 shares of the company’s stock worth $1,159,000 after acquiring an additional 1,196 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in Kiniksa Pharmaceuticals International during the second quarter worth $43,000. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.